Rocket Pharmaceuticals Expands Leadership with J&J and AstraZeneca Alumni to Strengthen Gene Therapy Commercialization

Leadership Expansion:
Rocket Pharmaceuticals has appointed Sarbani Chaudhuri as Chief Commercial and Medical Affairs Officer. Chaudhuri brings extensive experience from previously holding senior roles at Johnson & Johnson, AstraZeneca, Pfizer, and Novartis, focusing on oncology and rare diseases4.

Gene Therapy Milestones:

Rocket continues progressing its pipeline, including pivotal trials for conditions like Danon Disease, Fanconi Anemia, and Leukocyte Adhesion Deficiency-I (LAD-I).
The company is preparing for U.S. commercial launch, pending regulatory reviews for therapies like Kresladi and RP-L102, while addressing FDA's manufacturing requests4710.

Market Outlook:

The cell and gene therapy market is projected to reach $25.37 billion by 2025, driven by advances in scalability, manufacturing innovations, and regulatory support58.
Rocket is positioning itself as a commercial-stage biotech with a robust late-stage pipeline targeting high unmet medical needs in rare genetic diseases7.

Strategic Leadership:
Chaudhuri's experience in launching therapies like CAR-T and driving commercial strategies for blockbuster drugs positions Rocket well for its transition to commercialization4.

Regulatory Developments:
The FDA is reviewing additional manufacturing data for Kresladi, with Rocket expecting to resolve outstanding issues and proceed with its Biologics License Application for RP-L102 in 20254710.

Technological Progress:
Rocket utilizes innovative gene therapy platforms, including adeno-associated viral (AAV) and lentiviral (LV) vectors, showcasing long-term safety and efficacy data7.

Sources:

4. https://www.fiercepharma.com/marketing/rocket-boosts-preparations-gene-therapy-launch-new-commercial-chief-jj-astrazeneca

5. https://www.cryoport.com/bio-blog-top-10-industry-predictions-for-2025/

7. https://www.businesswire.com/news/home/20250227281067/en/Rocket-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Highlights-Recent-Progress

8. https://www.criver.com/eureka/cell-and-gene-therapy-whats-hot-2025

10. https://www.biopharmadive.com/news/rocket-pharma-fda-reject-gene-therapy-kresladi-manufacturing/720145/